Europe — EMA
Padcev (Enfortumab Vedotin)
Enfortumab vedotin, the active ingredient in Padcev, is an Antibody‑Drug Conjugate (ADC) presented as a sterile solution for intravenous infusion use.
Request sourcing
What is Enfortumab Vedotin?
Enfortumab vedotin, the active ingredient in Padcev, is an Antibody‑Drug Conjugate (ADC) presented as a sterile solution for intravenous infusion use. It treats locally advanced or metastatic uro‑urinary bladder cancer in adult patients who have received prior therapy. GNH USA supplies Padcev as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.
GNH USA supplies Padcev as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.
What is Enfortumab Vedotin used for?
Padcev is an ADC that targets the Nectin‑4 pathway in uro‑thelial carcinoma.
- Metastatic urothelial carcinoma: improves the overall response rate and survival in patients with previous treatment. - Locally distant uro‑cancer ( ): yield the same but the . - . - t . - t . -
